Drug Trial Radar · NCT05634746
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
Last checked: Nov 20, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
218
Actual
Start
Dec 29, 2022
Primary completion
Aug 12, 2024
Study completion Aug 12, 2024
Sponsor
- Lead sponsor
- Ellodi Pharmaceuticals, LPIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension. This study will evaluate the efficacy and safety of APT-1011 3 mg administered HS (hora somni, at bedtime) for the induction of response to treatment (symptomatic and histologic) over 24 weeks. The open-label extension will continue to evaluate long-term safety in subjects who consent to continue on open-label treatment with APT-1011.
Conditions
- Eosinophilic Esophagitis
Interventions
APT-1011Drug
APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient. Other Names: fluticasone propionate
Placebo oral tabletDrug
Placebo orally disintegrating tablet. Other Names: PBO
EsophagogastroduodenoscopyProcedure
Esophagogastroduodenoscopy (EGD) is a test that involves an endoscope, a lighted camera on the end of a tube, that is passed down a subject's throat to visualize their esophagus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Histological Remission (Co-Primary Outcome Measure)Time frame: Week 24
- Complete Symptomatic Response (Co-Primary Outcome Measure)Time frame: Week 24
Locations
60 sites in 2 countries. Site status is shown where the registry gives one.
Digestive Health Specialists
Dothan, Alabama
East View Medical Research LLC
Mobile, Alabama
Premier Allergy Asthma and Immunology
Scottsdale, Arizona
Del Sol Research Management, LLC.
Tucson, Arizona
Preferred Research Partners, Inc.
Little Rock, Arkansas
Arkansas Gastroenterology
North Little Rock, Arkansas
Om Research LLC
Camarillo, California
Providence Facey Medical Foundation
Mission Hills, California
United Medical Doctors
Murrieta, California
TriWest Research Associates, LLC
San Diego, California
Precision Research Institute, LLC
San Diego, California
Peak Gastroenterology Associates
Colorado Springs, Colorado
Western States Clinical Research, Inc.
Wheat Ridge, Colorado
Medical Research Center of Connecticut, LLC
Hamden, Connecticut
Nature Coast Clinical Research
Inverness, Florida
I.H.S Health, LLC
Kissimmee, Florida
Endoscopic Research Inc
Orlando, Florida
Revival Clinical Research
Orlando, Florida
Gastroenterology Associates of Central Georgia, LLC
Macon, Georgia
GI Alliance - Glenview
Glenview, Illinois
GI Alliance - Gurnee
Gurnee, Illinois
Deaconess Clinic Allergy
Evansville, Indiana
Gastroenterology Health Partners, PLLC
New Albany, Indiana
Velocity Clinical Research, Inc.
Overland Park, Kansas
MGG Group Co., Inc., Chevy Chase Clinical Research
Chevy Chase, Maryland
Gastro Center of Maryland, LLC
Columbia, Maryland
Velocity Clinical Research, Inc.
Rockville, Maryland
Boston Specialists
Boston, Massachusetts
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan
Henry Ford Health System
Novi, Michigan
Clinical Research Institute of Michigan, LLC
Troy, Michigan
Gastroenterology Associates of Western Michigan
Wyoming, Michigan
MNGI Digestive Health, P.A.
Plymouth, Minnesota
Clinical Research Professionals
Chesterfield, Missouri
Bozeman Health
Bozeman, Montana
Advanced Research Institute
Reno, Nevada
New Mexico Clinical Research & Osteoporosis Center, Inc.
Albuquerque, New Mexico
New York Gastroenterology Associates
New York, New York
UNC Clinical and Translational Research Center (CTRC)
Chapel Hill, North Carolina
Charlotte Gastroenterology & Hepatology, PLLC
Charlotte, North Carolina
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.